LOW-FLOW NOCTURNAL OXYGEN THERAPY FOR THE TREATMENT OF CENTRAL SLEEP APNEA IN CHRONIC HEART FAILURE: THE PAST, the PRESENT, and the FUTURE

Clicks: 6
ID: 337981
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #239 of 243 articles by views in Sleep & breathing = Schlaf & Atmung

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 243 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Central sleep apnea (CSA), commonly seen in patients with heart failure and reduced ejection fractions (HFrEF), is associated with hypoxia, heightened sympathetic activity, and poor clinical outcomes. While several CSA therapies reduce the apnea-hypopnea index, none have been shown to improve long-term important clinical outcomes. Nocturnal oxygen therapy (NOT) represents a physiologically sound approach to the treatment of CSA. Evidence supports the potential benefits of NOT in such patients, but no proof of its effectiveness on hard outcomes exists. Thus, there has been a longstanding need for a randomized controlled trial of NOT for CSA in HFrEF patients. The ideal trial would establish the rationale for NOT by measuring clinically meaningful outcomes, use rigorous methodologies such as double-blinding and a sham control, and optimize safety by delivering oxygen at doses that ameliorate hypoxemia and avoid hyperoxia. Such a trial (LOFT-HF NCT03745898) was indeed eventually sponsored by the National Institute of Heath and was initiated in 2018-2019. However, the trial was halted during the COVID-19 pandemic due to slow enrollment. Findings were recently published and did not provide a firm conclusion but suggested potential harm in the NOT arm based on a very small number of participants. Meanwhile, the American Academy of Sleep Medicine (AASM) published recently new treatment guidelines for CSA, suggesting use NOT in CSA. In this article, we attempt to reconcile the LOFT-HF trial findings with existing literature and the new AASM CSA management guidelines and discuss future research needs.
Reference Key
openalex_W7225003990 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shahrokh Javaheri, Rami Khayat, William Todd Abraham, Rui Wang, Susan S Redline
Are you one of these authors? Claim your profile
Journal Sleep & breathing = Schlaf & Atmung
Year 2026
DOI
10.1093/sleep/zsag287
URL
https://doi.org/10.1093/sleep/zsag287
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.